Drugs / NIBROZETONE
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT04525014 | Jan 2023 → Jul 2024 | brain cancer, childhood malignant neoplasm | EpicentRx, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02871843 | Feb 2017 → Oct 2019 | anaplastic oligodendroglioma, glioblastoma, oligodendroglioma | EpicentRx, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02801097 | Aug 2016 → Nov 2018 | metastatic malignant neoplasm | EpicentRx, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02518958 | Jul 2015 → May 2016 | cancer, lymphoma | EpicentRx, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02215512 | Feb 2015 → Nov 2016 | metastatic malignant neoplasm in the brain | EpicentRx, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02096341 | Apr 2014 → Jan 2016 | cancer, lymphoma | EpicentRx, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01359982 | Sep 2011 → Feb 2015 | cancer, lymphoma | EpicentRx, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05966194 | Apr 2024 → Jul 2027 expected | mucositis | EpicentRx, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03515538 | Jul 2018 → Oct 2019 | chemotherapy-induced oral mucositis | EpicentRx, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02452970 | Jul 2015 → May 2016 | cholangiocarcinoma | EpicentRx, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02489903 | Jun 2015 → Dec 2021 | malignant epithelial tumor of ovary, non-small cell lung carcinoma, small cell carcinoma | EpicentRx, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02096354 | May 2014 → Apr 2018 | colorectal cancer | EpicentRx, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05566041 | Aug 2022 → Dec 2025 overdue | small cell lung carcinoma | EpicentRx, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03699956 | Dec 2018 → Aug 2022 | small cell lung carcinoma | EpicentRx, Inc. | Terminated | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NIBROZETONE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3526802 ↗ |
| Known as | Abdnaz | ChEMBL registry synonym — accepted as the source's own label CHEMBL3526802 ↗ |
| Known as | Bromonitrozidine | “Bromonitrozidine (RRx-001) is a minimally toxic, NLRP3 inhibitor” PMID 36960054 ↗ Mar 2023 |
| Known as | Nibrozetona | ChEMBL registry synonym — accepted as the source's own label CHEMBL3526802 ↗ |
| Known as | Radiosensitizer rrx-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3526802 ↗ |
| Known as | RRx-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05566041 ↗ |
| Action | Activate | “turns on a number of beneficial genes” NCT02452970 ↗ |
| Modality | Other / unclassified | “INTRODUCTION: RRx-001 is a novel cysteine-targeted alkylating agent that releases nitric oxide (NO).” PMID 36529613 ↗ Dec 2022 |
| Route | Intravenous | “Patients were assigned to receive intravenous infusions of RRx-001 at increasing doses” PMID 26296952 ↗ Aug 2015 |
| Target | CD47 | “RRx-001 is a small molecule Myc inhibitor and down-regulates CD47 expression on tumor cells.” PMID 33569311 ↗ Jan 2021 |
| Target | MYC | “RRx-001 is a small molecule Myc inhibitor and down-regulates CD47 expression on tumor cells.” PMID 33569311 ↗ Jan 2021 |